Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab

NCT03030183 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions

DRUG: Zilucoplan (RA101495)

Sponsor

Ra Pharmaceuticals